



## **Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016**

**HAIFA, ISRAEL, January 26, 2016 --** [Pluristem Therapeutics Inc.](#) (NasdaqCM: PSTI , TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced that Dr. Karine Kleinhaus, the Company's Divisional VP, North America, will present at the [Bio CEO & Investor Conference](#) on February 8 at 8:30 am ET. The conference will take place on February 8 and 9, 2016 at the Waldorf Astoria in New York City. Investors and media interested in a meeting with Dr. Kleinhaus may contact Pluristem directly or investors may book a one-on-one meeting through the conference organizers.

### **About Pluristem Therapeutics**

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported positive clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.

### **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements when we discuss the findings of the study, the evidence they provide and their potential implications, such as the superiority of placenta-derived cells over those sourced from fat tissue and bone marrow and the potential power of placental cells to address complex diseases without harming the patient, and when we discuss our plans to advance into clinical studies of PLX-PAD cells in treating preeclampsia. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter

delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

**Contact:**

Pluristem Therapeutics Inc.  
Karine Kleinhaus, MD, MPH  
Divisional VP, North America  
1-914-512-4109  
[karinek@pluristem.com](mailto:karinek@pluristem.com)